These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25884438)

  • 41. The value of ESWAN in diagnosis and differential diagnosis of prostate cancer: Preliminary study.
    Xin JY; Gao SS; Liu JG; Sun CF; Han Y; Sun XH; Wang XZ; Wang B
    Magn Reson Imaging; 2017 Dec; 44():26-31. PubMed ID: 28782677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oxidised low-density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia.
    Asare GA; Owusu-Boateng E; Asiedu B; Amoah BY; Essendoh E; Otoo RY
    Andrologia; 2019 Sep; 51(8):e13321. PubMed ID: 31145504
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study.
    Guan Y; Wang X; Guan K; Wang D; Bi X; Xiao Z; Xiao Z; Shan X; Hu L; Ma J; Li C; Zhang Y; Shou J; Wang B; Qian Z; Xing N
    BMC Med Genomics; 2022 May; 15(Suppl 2):104. PubMed ID: 35513884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G
    Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
    Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
    Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia.
    Ge Y; Xu B; Cai H; Jing W; Ouyang Q; Yuan Q; Li X; Fan Y; Shen Y; Shi Q; Wang Q; Cui L; Yin X; Ma G
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2301-2310. PubMed ID: 36198834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer.
    Vermassen T; Van Praet C; Lumen N; Decaestecker K; Vanderschaeghe D; Callewaert N; Villeirs G; Hoebeke P; Van Belle S; Rottey S; Delanghe J
    Prostate; 2015 Feb; 75(3):314-22. PubMed ID: 25358590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
    Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determination of amino acids in urine of patients with prostate cancer and benign prostate growth.
    Sroka WD; Boughton BA; Reddy P; Roessner U; Słupski P; Jarzemski P; Dąbrowska A; Markuszewski MJ; Marszałł MP
    Eur J Cancer Prev; 2017 Mar; 26(2):131-134. PubMed ID: 27222937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
    Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
    DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urinary cholesterol excretion in men with benign prostatic hyperplasia and carcinoma of the prostate.
    Juengst D; Pickel A; Elsaesser E; Marx FJ; Karl HJ
    Cancer; 1979 Jan; 43(1):353-9. PubMed ID: 83906
    [No Abstract]   [Full Text] [Related]  

  • 58. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
    Jin W; Fei X; Wang X; Chen F; Song Y
    J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer.
    Li C; Zang T; Wrobel K; Huang JT; Nabi G
    Anal Bioanal Chem; 2015 May; 407(12):3393-404. PubMed ID: 25724369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer.
    Vermassen T; Van Praet C; Vanderschaeghe D; Maenhout T; Lumen N; Callewaert N; Hoebeke P; Van Belle S; Rottey S; Delanghe J
    Electrophoresis; 2014 Apr; 35(7):1017-24. PubMed ID: 24254641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.